Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria

Infection and Immunity

Volumn 80, Issue 5, 2012, Pages 1900-1908

  Rono, Josea ^a,b   Färnert, Anna ^b   Olsson, Daniel ^a   Osier, Faith ^a   Rooth, Ingegerd ^c   Persson, Kristina E M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c Nyamisati Malaria Research   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CELL INVASION; CHILD; ERYTHROCYTE; FEMALE; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA; MALE; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANZANIA;

ADOLESCENT; ADULT; AGING; ANIMALS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; RISK FACTORS; TANZANIA; YOUNG ADULT;

EID: 84861167354     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06190-11     Document Type: Article

References (54)

1. Agnandji ST, et al. 2011. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863-1875.
2. Bereczky S, et al. 2007. Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect. 9:103-110.
3. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. 1994. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. 180:389-393.
4. Bolad A, et al. 2003. Antibody-mediated in vitro growth inhibition of field isolates of Plasmodium falciparum from asymptomatic children in Burkina Faso. Am. J. Trop. Med. Hyg. 68:728-733.
5. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172:1633-1641.
6. Brown GV, Anders RF, Mitchell GF, Heywood PF. 1982. Target antigens of purified human immunoglobulins which inhibit growth of Plasmodium falciparum in vitro. Nature 297:591-593.
7. Chappel JA, Holder AA. 1993. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60:303-311.
8. Clough B, Atilola FA, Pasvoi G. 1998. The role of rosetting in the multiplication of Plasmodium falciparum: rosette formation neither enhances nor targets parasite invasion into uninfected red cells. Br. J. Haematol. 100:99-104.
9. Cohen S, Butcher GA, Crandall RB. 1969. Action of malarial antibody in vitro. Nature 223:368-371.
10. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737.
11. Corran PH, et al. 2004. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a crosssectional survey in The Gambia. Infect. Immun. 72:6185-6189.
12. Cowman AF, Crabb BS. 2006. Invasion of red blood cells by malaria parasites. Cell 124:755-766.
13. Crompton PD, et al. 2010. In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali. Infect. Immun. 78:737-745.
14. Crosnier C, et al. 2011. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480:534-537.
15. Deans AM, Rowe JA. 2006. Plasmodium falciparum: rosettes do not protect merozoites from invasion-inhibitory antibodies. Exp. Parasitol. 112:269-273.
16. de Koning-Ward TF, et al. 2003. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J. Exp. Med. 198:869-875.
17. Dent AE, et al. 2008. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 3:e3557.
18. Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria. Clin. Microbiol. Rev. 22:13-36.
19. Duraisingh MT, et al. 2003. Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes. EMBO J. 22:1047-1057.
20. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. 1999. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21:133-139.
21. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 7:e1000218.
22. Franzen L, et al. 1989. Enhancement or inhibition of Plasmodium falciparum erythrocyte reinvasion in vitro by antibodies to an asparagine rich protein. Mol. Biochem. Parasitol. 32:201-211.
23. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. 1997. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186:1689-1699.
24. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69: 3286-3294.
25. John CC, et al. 2004. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J. Immunol. 173:666-672.
26. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. 1989. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83:293-303.
27. McCallum FJ, et al. 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 3:e3571.
28. Murhandarwati EE, et al. 2009. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semiimmune individuals in Vietnam. Infect. Immun. 77:4510-4517.
29. Nair M, et al. 2002. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J. Mol. Biol. 322:741-753.
30. Nair S, et al. 2010. Genetic changes during laboratory propagation: copy number at the reticulocyte-binding protein 1 locus of Plasmodium falciparum. Mol. Biochem. Parasitol. 172:145-148.
31. Narum DL, et al. 2000. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect. Immun. 68:1964-1966.
32. Nery S, et al. 2006. Expression of Plasmodium falciparum genes involved in erythrocyte invasion varies among isolates cultured directly from patients. Mol. Biochem. Parasitol. 149:208-215.
33. Nwuba RI, et al. 2002. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect. Immun. 70:5328-5331.
34. O'Donnell RA, et al. 2001. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412.
35. Patarapotikul J, Tharavanij S, Poonthong C. 1983. Multiple strains of Plasmodium falciparum are necessary for the growth inhibition assay. Southeast Asian J. Trop. Med. Public Health 14:149-153.
36. Perraut R, et al. 2005. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. 191:264-271.
37. Persson KE. 2010. Erythrocyte invasion and functionally inhibitory antibodies in Plasmodium falciparum malaria. Acta Trop. 114:138-143.
38. Persson KE, Lee CT, Marsh K, Beeson JG. 2006. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J. Clin. Microbiol. 44:1665-1673.
39. Persson KE, et al. 2008. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J. Clin. Invest. 118:342-351.
40. Polley SD, et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728.
41. Ribacke U, et al. 2007. Genome wide gene amplifications and deletions in Plasmodium falciparum. Mol. Biochem. Parasitol. 155:33-44.
42. Sardarian A, et al. 2003. Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. Org. Biomol. Chem. 1:960-964.
43. Saul A. 1987. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol. 9:1-9.
44. Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA. 1999. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 60:135-141.
45. Singh S, et al. 2006. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74:4573-4580.
46. Stubbs J, et al. 2005. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 309:1384-1387.
47. Taylor TE, et al. 1992. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin. Exp. Immunol. 90:357-362.
48. Tebo AE, Kremsner PG, Luty AJ. 2001. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp. Parasitol. 98:20-28.
49. Triglia T, Duraisingh MT, Good RT, Cowman AF. 2005. Reticulocytebinding protein homologue 1 is required for sialic acid-dependent invasion into human erythrocytes by Plasmodium falciparum. Mol. Microbiol. 55:162-174.
50. Uthaipibull C, et al. 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307:1381-1394.
51. Vekemans J, Ballou WR. 2008. Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines 7:223-240.
52. Wahlgren M, Carlson J, Udomsangpetch R, Perlmann P. 1989. Why do Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte rosettes? Parasitol. Today 5:183-185.
53. Wilson RJ, Phillips RS. 1976. Method to test inhibitory antibodies in human sera to wild populations of Plasmodium falciparum. Nature 263: 132-134.
54. World Health Organization. 2010. World malaria report. World Health Organization, Geneva, Switzerland.